B-cell Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for B-cell Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-11-19Clinical Trial Update: Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL [Phase 2]
Phase 2 clinical trial evaluating maintenance therapy with decitabine, venetoclax, and blinatumomab after hematopoietic stem cell transplant…
-
CLINICAL_TRIALS research · 2024-11-15Clinical Trial Update: Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies [Phase 1]
Phase 1 study of VIP943 in adults with advanced CD123+ hematologic malignancies is currently recruiting, including acute myeloid leukemia, B…
-
CLINICAL_TRIALS research · 2024-11-07Clinical Trial Update: JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia [NA]
Clinical trial update for JY231 Injection studying its use in relapsed or refractory B-cell lymphoma and B-cell acute lymphoblastic leukemia…
-
CLINICAL_TRIALS trial_result · 2024-11-05Clinical Trial Update: Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission. [Phase 2]
A phase 2 trial is evaluating combining Inaticabtagene Autoleucel CAR-T therapy with autologous hematopoietic stem cell transplantation in a…
-
CLINICAL_TRIALS research · 2024-10-26Clinical Trial Update: Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease. [EARLY_Phase 1]
An early-phase trial evaluating the safety and efficacy of PRG-2302 for refractory or relapsed B-cell acute lymphoblastic leukemia, currentl…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-10-26Clinical Trial Update: Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation [NA]
Trial evaluating Blinatumomab as maintenance therapy for high-risk B-cell acute lymphoblastic leukemia after allogeneic hematopoietic cell t…
-
CLINICAL_TRIALS trial_result · 2024-10-17Clinical Trial Update: Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL [Phase 2]
A Phase 2 trial evaluating sequential CD19 and CD22 CAR-T therapy for newly diagnosed Philadelphia chromosome–positive B-cell acute lymphobl…
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL [Phase 1]
Phase 1 clinical trial evaluating CD19-targeted CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia.
-
CLINICAL_TRIALS research · 2024-10-10Clinical Trial Update: Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the safety and efficacy of an unnamed CAR T cell therapy in patients with relapsed or refractory B-…
-
CLINICAL_TRIALS research · 2024-09-23Clinical Trial Update: Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia [Phase 2, Phase 3]
This clinical trial update outlines a Phase 2/3 efficacy study of blinatumomab for newly diagnosed pediatric B-cell acute lymphoblastic leuk…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL [Phase 2]
A Phase 2 trial evaluating reduced-dose chemotherapy followed by blinatumomab as induction therapy for newly diagnosed Philadelphia-negative…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
The trial update indicates that Inaticabtagene Autoleucel is being studied for adults with relapsed or refractory B-cell acute lymphoblastic…
-
CLINICAL_TRIALS research · 2024-08-28Clinical Trial Update: Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma [Phase 1]
A Phase 1 trial in Belarus is evaluating a pilot CD19-targeted CAR-T cell therapy for children and young adults with relapsed/refractory B-c…
-
CLINICAL_TRIALS research · 2024-08-19Clinical Trial Update: Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia [EARLY_Phase 1]
This is an early Phase 1 trial update for Hema-NeoTIL01 cell infusion therapy in relapsed/refractory acute leukemia, including acute myeloid…
-
CLINICAL_TRIALS research · 2024-08-15Clinical Trial Update: Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL [Phase 2]
Phase 2 study evaluating sequencing of Blinatumomab, Venetoclax, and Inotuzumab Ozogamicin for B-cell acute lymphoblastic leukemia is curren…
-
CLINICAL_TRIALS withdrawal · 2024-07-19Clinical Trial Update: Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL [Phase 1, Phase 2]
The Phase 1/2 trial evaluating CAR19 regulatory T cells (CAR19-tTreg) for relapsed/refractory CD19+ B-cell acute lymphoblastic leukemia has …
-
CLINICAL_TRIALS research · 2024-07-16Clinical Trial Update: CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating a CD19 and CD20 bispecific CAR T cell therapy for relapsed or refractory B-cell hematologic malignancies…
-
CLINICAL_TRIALS research · 2024-07-16Clinical Trial Update: The Use of Blinatumomab in Patients With NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation [NA]
Clinical trial evaluating blinatumomab for patients with NGS-MRD positive relapsed B-cell acute lymphoblastic leukemia after autologous or a…
-
CLINICAL_TRIALS withdrawal · 2024-07-12Clinical Trial Update: Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy [Phase 1, Phase 2]
A Phase 1/Phase 2 trial evaluating Interferon-Beta-1a (FP-1201) to prevent toxicities after CD19-directed CAR T-cell therapy has been withdr…
-
CLINICAL_TRIALS research · 2024-05-29Clinical Trial Update: Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating reinfusion of tisagenlecleucel in combination with an anti-PD1 antibody for children, adolescents, and…
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations [Phase 3]
Phase 3 clinical trial update evaluating combination chemotherapy in young patients with newly diagnosed high-risk B-cell acute lymphoblasti…
-
CLINICAL_TRIALS trial_result · 2023-11-29Clinical Trial Update: CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. [Phase 1, Phase 2]
Phase 1/2 clinical trial investigating a CD19/CD22-targeted CAR-T therapy for B-cell acute lymphoblastic leukemia (B-ALL).
-
CLINICAL_TRIALS trial_result · 2023-02-24Clinical Trial Update: CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL [Phase 1, Phase 2]
Clinical trial update for CD19-targeted T-CAR therapy in children and young adults with relapsed/refractory B-ALL, currently in Phase 1/Phas…
-
CLINICAL_TRIALS trial_result · 2023-02-22Clinical Trial Update: Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL [Phase 1, Phase 2]
Clinical trial evaluating a bispecific CD19/CD22 CAR-T therapy for children and young adults with refractory/relapsed B-ALL, across Phase 1 …
-
CLINICAL_TRIALS trial_result · 2023-01-25Clinical Trial Update: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia [Phase 2]
A Phase 2 trial evaluating Blinatumomab with either combination chemotherapy or Dasatinib, Prednisone, and Blinatumomab in older patients wi…